Using technology to address recruitment issues in the clinical trial process

Area of Science:

• Drug discovery and development
• Clinical trial management
• Pharmaceutical economics

Background:

• The drug discovery and development pipeline is lengthy, often exceeding ten years.
• The clinical phase constitutes the majority of this development time.
• Patient recruitment is a significant bottleneck, consuming at least three years of the clinical trial duration.

Purpose of the Study:

• To investigate the feasibility of shortening drug development timelines.
• To analyze the impact of reduced clinical trial durations on market entry.
• To identify potential strategies for accelerating patient recruitment in clinical trials.

Main Methods:

• Analysis of historical drug development data.
• Examination of clinical trial recruitment timelines.
• Economic modeling of the value of accelerated drug development.

Main Results:

• Clinical development, including regulatory processes, averages over six years per drug.
• Patient recruitment alone accounts for a substantial portion of clinical trial time.
• Each month of accelerated development is valued at approximately US $25 million in additional revenue.

Conclusions:

• Reducing drug development timelines, particularly patient recruitment, is a critical area for pharmaceutical innovation.
• Accelerating the clinical trial process offers significant economic benefits.
• Further research into optimizing patient recruitment strategies is warranted.